Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29791018 | 1.00 | PRKCI (0.49) | PRKCIRAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL2140286 | 0.90 | CTNNB1 (0.47) | PRKCIRAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL80222 | 0.90 | PRKCI (0.46) | PRKCIRAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL13945187 | 0.86 | PRKCI (0.46) | PRKCIRAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL17726436 | 0.86 | CHRM2 (0.55) | PRKCIRAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL30922323 | 0.85 | PRKCI (0.51) | PRKCIRAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL317341 | 0.85 | PRKCI (0.51) | PRKCIRAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL8938493 | 0.83 | ALDH1A1 (0.39) | PRKCIRAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL292900 | 0.82 | RAB9A (0.45) | PRKCIRAB9APOLBNPC1KDM1A | |
| SCHEMBL1276487 | 0.82 | RAB9A (0.46) | PRKCIRAB9APOLBNPC1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113122061-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| US-20080269505-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-10-30 | — | — | US | claimed |
| EP-1877393-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-01-16 | — | — | EP | claimed |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-30 | — | — | US | claimed |
| WO-2007076158-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | claimed |
| CN-118922418-A | Tetrahydroisoquinoline derivatives serving as pan-KRAS inhibitor as well as preparation method and application thereof | 思路迪生物医药(上海)有限公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2023169481-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AS PAN-KRAS INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 思路迪生物医药(上海)有限公司 | 2023-09-14 | — | — | WO | disclosed |
| CN-114874201-B | Pan-KRAS inhibitor and preparation and application thereof | 思路迪生物医药(上海)有限公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-114907389-A | Boronic acid derivatives | 首药控股(北京)股份有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-114874201-A | Pan-KRAS inhibitor and preparation and application thereof | 思路迪生物医药(上海)有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-113122061-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| CN-107721954-B | Novel preparation method of darifenacin intermediate 2, 3-dihydro-5-benzofuran acetic acid | 内蒙古京东药业有限公司 | 2020-02-14 | — | — | CN | disclosed |
| EP-0388054-A1 | Pyrrolidine derivatives | Pfizer Limited (GB) | 1990-09-19 | — | — | EP | disclosed |
| EP-0376358-A1 | Muscarinic receptor antagonists | PFIZER INC. (US) | 1990-07-04 | — | — | EP | disclosed |
| WO-1990005133-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1990-05-17 | — | — | WO | disclosed |
| WO-1990004583-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1990-05-03 | — | — | WO | disclosed |
| EP-0365093-A1 | Muscarinic receptor antagonists | PFIZER INC. (US) | 1990-04-25 | — | — | EP | disclosed |
| EP-0364123-A1 | Muscarinic receptor antagonists | Pfizer Limited (GB) | 1990-04-18 | — | — | EP | disclosed |
| CN-1039415-A | New 1, the preparation method of 3-3-disubstituted piperidine derivatives | PFIZER (GB) | 1990-02-07 | — | — | CN | disclosed |
| EP-0350309-A1 | Piperidine derivatives | Pfizer Limited (GB) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | CHRNE, CHRM3, CHRM2 | PRKCI 3442/4885RAB9A 3273/4885POLB 2444/4885 |
| US-20080269505-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | PRKCI 4076/4885RAB9A 956/4885POLB 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.